In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 15 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Concurrent Initiation of Intra-aortic Balloon Pumping with Extracorporeal Membrane Oxygenation Reduced In-hospital Mortality in Postcardiotomy Cardiogenic Shock

Session Rapid Fire 3 - Acute heart failure

Speaker Kai Chen

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure: Non-pharmacological Treatment
  • Session type : Rapid Fire Abstracts

Authors : K Chen (Beijing,CN), HW Tang (Beijing,CN), JF Hou (Beijing,CN), SS Hu (Beijing,CN)

Authors:
K Chen1 , HW Tang1 , JF Hou1 , SS Hu1 , 1Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, department of cardiac surgeon - Beijing - China ,

Citation:

Purpose: We analyzed the outcomes, predictive factors and complications of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) use for postcardiotomy cardiac shock (PCS).
Methods: A total of 152 adult subjects who received VA-ECMO (>24 hours) for PCS in our hospital were consecutively included. Baseline characteristics were compared between survivors with non-survivors, and logistic regression was performed to identify predictive factors for in-hospital mortality.
Results: The mean age of the subjects was 49.5±14.1 years. The main surgical procedures were heart transplantation (32.2%), coronary artery bypass graft (17%) and valvular surgery (11.8%). Intra-aortic balloon pumping(IABP) was initiated concurrently with ECMO in 32.2% subjects and sequentially in 18.4% subjects. The ECMO weaning rate was 56.6%, and the in-hospital mortality was 52.0%. When compared with non-survivors, survivors had less hypertension (15.1% vs. 35.4%, p=0.004), pre-ECMO secondary thoracotomy (19.2% vs. 39.2%, p=0.007), pre-ECMO cardiac arrest/ventricular fibrillation (11.0% vs. 34.2%, p=0.001), bedside implantation of ECMO (11.0% vs. 41.8%, p<0.001), and more transplant procedure (45.2% vs. 20.3%, p=0.001), concurrent IAPB initiation with ECMO (41.1% vs. 24.1%, p=0.025). Multivariate logistic regression indicated concurrent IABP initiation with ECMO was the only independent protective factor for in-hospital mortality (OR=0.375, p=0.041, 95% CI: 0.146-0.963). Concurrent IABP initiation with ECMO had less need for continuous renal replacement therapy (30.6% vs. 49.3%, p=0.039) and less neurological complications (8.2% vs. 22.7%, p=0.035), but more thrombosis complications (18.4% vs. 2.7%, p=0.007).
Conclusion: Concurrent initiation of IABP with ECMO provides better short-term survival for PCS, with reduced peripheral perfusion complications.

This content is currently on FREE ACCESS, enjoy another 15 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are